Register for our free email digests:
Division of Pfizer Inc.
Latest From Vascular Solutions Inc.
Device Debuts: Spinal Innovation From NuVasive, Life Spine; Teleflex Targets EuroPCR For Arrow AC3 Optimus; Abiomed Pushes 3-G Impella
This edition of Device Debuts covers the innovative devices introduced into commercial markets since the mid-April, typically a busy time for product launches as it coincides with spring's big medical meetings. This includes a series of spine-surgery technologies showcased at the AANS meeting and devices that support blood circulation during interventions that were featured at EuroPCR and SCAI.
The purchase price of $56 a share in cash is a modest 16% premium over Vascular Solutions' 90-day average price. Vascular Solutions' CEO says uncertainty about the future leadership of the company compelled it to consider acquisition offers.
Off-label marketing and kickbacks may no longer be the top targets of government healthcare fraud investigations as more companies are being hit with subpoenas for pricing information.
Attorneys for former Acclarent executives William Facteau and Patrick Fabian have filed a request that their convictions on off-label marketing charges either be set aside or that they be granted a new trial, citing other recent off-label trials and misconduct by the government.
- Therapeutic Areas
- Wyeth-Ayerst Laboratories
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Joseph M Mahady, Pres.
Mark Lee, PhD, SVP, Bus. Dev., Pharma & Head, Worldwide Licensing
Gary L Stiles, MD, EVP, CMO
Geno Germano, Pres., US & Gen. Manager
- Contact Info
Phone: (610) 902-1200
500 Arcola Rd.
Collegeville, PA 19426
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.